ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1734

Identification of Sjögren’s Disease-Associated T Cell Receptors Through Deep Sequencing and Single-Cell Transcriptomics

Ananth Aditya Jupudi1, Michelle Joachims1, Christina Lawrence1, Charmaine Lopez-Davis1, Bhuwan Khatri1, Astrid Rasmussen1, Lida Radfar2, Kiely Grundahl1, R. Hal Scofield2, Judith James1, Joel Guthridge1, Christopher Lessard1, Linda F. Thompson1 and A. Darise Farris1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2University of Oklahoma Health Sciences Center, Oklahoma City, OK

Meeting: ACR Convergence 2022

Keywords: autoantigens, Bioinformatics, genomics, Sjögren's syndrome, T Cell

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2022

Title: T Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Sjögren’s disease (SjD) is a chronic rheumatic autoimmune disorder that primarily targets the lacrimal and salivary glands (SG) resulting in dry eyes and dry mouth. The SG tissue of SjD patients is characterized by the presence of hallmark focal lymphocytic infiltrates predominated by CD4+ T cells. This implies a pathogenic role for these cells which is further corroborated by the association of SjD with HLA DR3/DQ2. In this study, we aim to identify T cell receptors (TCRs) with shared antigen-specificity in SjD cases.

Methods: Peripheral blood (PB) samples were collected from 19 cases (16 DR3+DQ2+, 2 DR3–/DQ2–, 1 DR3+DQ2–) meeting the 2016 ACR/EULAR classification criteria for SjD and 19 DR3+DQ2+ matched healthy controls (HC). CD3+CD4+CD45RA– antigen-experienced T cells were bulk-sorted from subjects followed by RNA extraction and cDNA synthesis using the SMARTSeq system. TCRβ libraries were generated for TCR deep sequencing. We implemented the ‘Molecular Identifier Guided Error Correction pipeline’ (MIGEC) to extract CDR3 sequences, V/J segment usage, and clonotype information from raw sequencing data. The incorporation of unique molecular identifiers (UMIs) into cDNA allowed for the correction of amplification bias and sequencing errors. In addition to the PB data, we included paired TCR α and β sequences derived from the SG of 20 SjD cases (n=10 by TCR RT-PCR, n=10 by single-cell RNAseq) for analysis. We prepared a curated meta-dataset from all available TCRs to identify those with shared antigen specificity using the ‘GLIPH2’ (Grouping of Lymphocyte Interactions by Paratope Hotspots) algorithm.

Results: PB-TCR deep sequencing data from 12 SjD cases and 12 HC passed quality control. We analyzed 1,877,614 CDR3β chain sequences using GLIPH2 and identified 55,419 TCR-clusters with shared antigen-specificity found exclusively in the patient TCR repertoire and not in HCs. Of these, 215 clusters contained TCRs from ≥3 SjD cases that shared amino acid sequence similarity and had significant GLIPH2 scores for clonal expansion, cluster size, Vb gene enrichment, and conserved CDR3 length. Furthermore, we discovered that 6 clusters with significant GLIPH2 scores for the same features contained TCRs that were commonly enriched in both the PB and SG tissue of patients. Notably, 3 TCRs were found to be enriched both in the blood and SG of the same patient. One of these was part of a clonal expansion in the SG, over-represented in PB, and expressed dual TCRα chains.

Conclusion: This study presents evidence of clonally-expanded T cells containing dual TCRα chains in the affected SG tissue and peripheral blood of the same patient. Such TCRs have been proposed to contribute to autoimmunity in several studies. We discovered an SjD-associated TCR repertoire shared between the SG and PB across multiple patients. Furthermore, we found disease-associated TCRs enriched in the PB of SjD cases. These data corroborate the systemic nature of SjD and enable the discovery of shared SjD T cell epitopes.


Disclosures: A. Jupudi, None; M. Joachims, None; C. Lawrence, None; C. Lopez-Davis, None; B. Khatri, None; A. Rasmussen, None; L. Radfar, None; K. Grundahl, None; R. Scofield, None; J. James, Bristol-Myers Squibb(BMS), AstraZeneca, Novartis, Progentec Biosciences; J. Guthridge, None; C. Lessard, Janssen; L. Thompson, None; A. Farris, Janssen.

To cite this abstract in AMA style:

Jupudi A, Joachims M, Lawrence C, Lopez-Davis C, Khatri B, Rasmussen A, Radfar L, Grundahl K, Scofield R, James J, Guthridge J, Lessard C, Thompson L, Farris A. Identification of Sjögren’s Disease-Associated T Cell Receptors Through Deep Sequencing and Single-Cell Transcriptomics [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/identification-of-sjogrens-disease-associated-t-cell-receptors-through-deep-sequencing-and-single-cell-transcriptomics/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identification-of-sjogrens-disease-associated-t-cell-receptors-through-deep-sequencing-and-single-cell-transcriptomics/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology